After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

(Reuters) - President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from ...

Alexion Pharmaceuticals v Amgen (UPC_Coa-405/2024) and Alexion Pharmaceuticals v Samsung Bioepis NL BV (UPC_CoA-402/2024); December 20, 2024.

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

In its Thousand Oaks hometown in California, it was far and away the biggest employer, with 1 in 10 of the town folk working for Amgen. It built sites throughout Europe and Asia, and became even ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Earlier patent litigation can be reformed to reflect similar success across Europe, resulting in accelerated US biosimilar ...

Runner-up finishes at the US Open, Amgen Irish Open and BMW Championship were among 10 ... while he will make an eighth consecutive Ryder Cup appearance for Team Europe later this year at Bethpage ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.